HRMY 34.28 (+1.15%)
US4131971040BiotechnologyBiotechnology

Harmony Biosciences Holdings (HRMY) Stock Highlights

34.28 | +1.15%
2024-12-21 03:32:15
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The companys product WAKIX (pitolisant), is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and used for the treatment of cataplexy in adult patients with narcolepsy.

Statistics

Range Today
33.48 34.97
Volume Today 2.98M
Range 1 Year
28.14 41.61
Volume 1 Year 118.93M
Range 3 Year
18.61 62.08
Volume 3 Year 416.44M
Range 10 Year
18.61 62.08
Volume 10 Year 512.3M

Highlights

Market Capitalization 2.06B (mid)
Floating Shares 44.06M
Current Price 34.28
Price To Earnings 16.1
Price To Revenue 2.69
Price To Book 3.45
Earnings Per Share 2.18
Payout Ratio 0%

Performance

Latest +1.15%
1 Month +5.64%
3 Months -12.08%
6 Months +19.36%
1 Year +2.3%
3 Years -15.63%
5 Years -14.28%
10 Years -14.28%

Benchmarks


Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.